{"disease":{"id":"advanced-malignant-tumors","name":"advanced malignant tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07480733","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05779163","title":"A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":468,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT06764771","title":"A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":437,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06877650","title":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":436,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06770881","title":"JSKN033 in Chinese Subjects with Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05728541","title":"Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":367,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04708210","title":"Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":256,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT04956926","title":"Clinical Study of JS201 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":244,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05198817","title":"A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05229497","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05214482","title":"A Study of AK112 in Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06962553","title":"Nurses' Competence and Role in Survival Prediction and Prognostic Communication","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT05396391","title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT05277454","title":"Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","has_results":false},{"nct_id":"NCT06717750","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","has_results":false},{"nct_id":"NCT04328506","title":"Bioequivalency Study of CM082 Tablet in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT07038005","title":"A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT06571422","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06226363","title":"Phase I Study of LNF1901 in Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":82,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT05886374","title":"A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT05102006","title":"A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT04226066","title":"Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Tasly Tianjin Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07028047","title":"Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04060472","title":"Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Dong Wang","has_results":false},{"nct_id":"NCT06223841","title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT04908046","title":"A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06573294","title":"Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT05773937","title":"A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06499350","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"FindCure Biosciences (ZhongShan) Co., Ltd.","has_results":false},{"nct_id":"NCT05036798","title":"Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05354076","title":"Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06658951","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"UTC Therapeutics Inc.","has_results":false},{"nct_id":"NCT02045095","title":"A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05326035","title":"A Study of WJ05129 in Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Suzhou Junjing BioSciences Co., Ltd.","has_results":false},{"nct_id":"NCT05223231","title":"Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT05193721","title":"A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05991583","title":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT04126668","title":"A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT07010523","title":"Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04338659","title":"A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT06231550","title":"A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"FindCure Biosciences (ZhongShan) Co., Ltd.","has_results":false},{"nct_id":"NCT07399769","title":"Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shenzhen University General Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}